Variability in nicotine conditioned place preference and stress-induced reinstatement in mice: Effects of sex, initial chamber preference, and guanfacine.
Adrenergic alpha-2 Receptor Agonists
/ pharmacology
Amygdala
/ drug effects
Animals
Conditioning, Classical
/ drug effects
Cytoskeletal Proteins
/ metabolism
Female
Guanfacine
/ pharmacology
Male
Mice
Nerve Tissue Proteins
/ metabolism
Nicotine
/ pharmacology
Nucleus Accumbens
/ drug effects
Sex Factors
Stress, Psychological
/ physiopathology
Tobacco Use Disorder
/ physiopathology
conditioned place preference
guanfacine
nicotine
reinstatement
sex differences
stress
Journal
Genes, brain, and behavior
ISSN: 1601-183X
Titre abrégé: Genes Brain Behav
Pays: England
ID NLM: 101129617
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
28
05
2019
revised:
25
07
2019
accepted:
27
07
2019
pubmed:
1
8
2019
medline:
5
1
2021
entrez:
1
8
2019
Statut:
ppublish
Résumé
Relapse to smoking occurs at higher rates in women compared with men, especially when triggered by stress. Studies suggest that sex-specific interactions between nicotine reward and stress contribute to these sex differences. Accordingly, novel treatment options targeting stress pathways, such as guanfacine, an α2-adrenergic receptor agonist, may provide sex-sensitive therapeutic effects. Preclinical studies are critical for elucidating neurobiological mechanisms of stress-induced relapse and potential therapies, but rodent models of nicotine addiction are often hindered by large behavioral variability. In this study, we used nicotine conditioned place preference to investigate stress-induced reinstatement of nicotine preference in male and female mice, and the effects of guanfacine on this behavior. Our results showed that overall, nicotine induced significant place preference acquisition and swim stress-induced reinstatement in both male and female mice, but with different nicotine dose-response patterns. In addition, we explored the variability in nicotine-dependent behaviors with median split analyses and found that initial chamber preference in each sex differentially accounted for variability in stress-induced reinstatement. In groups that showed significant stress-induced reinstatement, pretreatment with guanfacine attenuated this behavior. Finally, we evaluated neuronal activation by Arc immunoreactivity in the infralimbic cortex, prelimbic cortex, anterior insula, basolateral amygdala, lateral central amygdala and nucleus accumbens core and shell. Guanfacine induced sex-dependent changes in Arc immunoreactivity in the infralimbic cortex and anterior insula. This study demonstrates sex-dependent relationships between initial chamber preference and stress-induced reinstatement of nicotine conditioned place preference, and the effects of guanfacine on both behavior and neurobiological mechanisms.
Identifiants
pubmed: 31364813
doi: 10.1111/gbb.12601
pmc: PMC8045136
mid: NIHMS1684689
doi:
Substances chimiques
Adrenergic alpha-2 Receptor Agonists
0
Cytoskeletal Proteins
0
Nerve Tissue Proteins
0
activity regulated cytoskeletal-associated protein
0
Guanfacine
30OMY4G3MK
Nicotine
6M3C89ZY6R
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e12601Subventions
Organisme : NIMH NIH HHS
ID : R01 MH077681
Pays : United States
Organisme : NIAAA NIH HHS
ID : P50 AA015632
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : NIDA NIH HHS
ID : P50 DA033945
Pays : United States
Organisme : NIDA NIH HHS
ID : DA14241
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007205
Pays : United States
Organisme : NIDA NIH HHS
ID : DP1 DA050986
Pays : United States
Organisme : NIDA NIH HHS
ID : DA043943
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA014241
Pays : United States
Organisme : NIDA NIH HHS
ID : DA033945
Pays : United States
Organisme : NIMH NIH HHS
ID : MH077681
Pays : United States
Organisme : NIDA NIH HHS
ID : F30 DA043943
Pays : United States
Organisme : NIAAA NIH HHS
ID : P01 AA027473
Pays : United States
Organisme : NIDA NIH HHS
ID : DA037566
Pays : United States
Organisme : NIDA NIH HHS
ID : R37 DA014241
Pays : United States
Organisme : NIGMS NIH HHS
ID : GM007205
Pays : United States
Informations de copyright
© 2019 John Wiley & Sons Ltd and International Behavioural and Neural Genetics Society.
Références
BMC Bioinformatics. 2006 Mar 09;7:123
pubmed: 16526949
Acta Physiol Pharmacol Neerl. 1955 Nov;4(3):442-4
pubmed: 13301816
J Neurosci. 2007 Nov 7;27(45):12358-66
pubmed: 17989300
Pharmacol Biochem Behav. 2008 Mar;89(1):94-100
pubmed: 18086490
Addiction. 2003 Jun;98(6):847-55
pubmed: 12780373
J Neurosci. 1988 Nov;8(11):4287-98
pubmed: 2903226
Neuropsychopharmacology. 2014 Nov;39(12):2799-815
pubmed: 24896614
Biol Psychiatry. 2008 Jun 1;63(11):1005-6
pubmed: 18482610
Pharmacol Biochem Behav. 2015 Nov;138:80-90
pubmed: 26410616
Brain Res. 2005 Jul 27;1051(1-2):90-9
pubmed: 15993862
Neuropsychopharmacology. 2018 May;43(6):1267-1275
pubmed: 29114104
Cereb Cortex. 2010 Nov;20(11):2560-7
pubmed: 20139149
Trends Pharmacol Sci. 2003 Sep;24(9):493-9
pubmed: 12967775
Brain Res Rev. 2009 Mar;59(2):253-77
pubmed: 18762212
Neuropsychopharmacology. 2016 Jan;41(1):335-56
pubmed: 25976297
Eur J Neurosci. 2000 Jan;12(1):292-302
pubmed: 10651884
Eur J Neurosci. 2008 Jul;28(2):342-52
pubmed: 18702705
J Pharmacol Exp Ther. 2007 Jul;322(1):399-407
pubmed: 17446302
Psychopharmacology (Berl). 2013 Apr;226(4):763-8
pubmed: 22526543
Prog Neuropsychopharmacol Biol Psychiatry. 2016 Feb 4;65:260-8
pubmed: 25912856
Psychopharmacology (Berl). 2004 Apr;173(1-2):98-104
pubmed: 14727001
Biol Psychiatry. 2008 Jan 15;63(2):164-71
pubmed: 17570348
Psychopharmacology (Berl). 2017 Jan;234(2):187-198
pubmed: 27695921
J Pharmacol Exp Ther. 1983 Jul;226(1):291-302
pubmed: 6864548
Psychopharmacology (Berl). 2006 Mar;184(3-4):456-63
pubmed: 16463055
Exp Clin Psychopharmacol. 2013 Aug;21(4):269-76
pubmed: 23834551
Neuron. 1995 Feb;14(2):433-45
pubmed: 7857651
Cochrane Database Syst Rev. 2013 May 31;(5):CD009329
pubmed: 23728690
Behav Brain Res. 2016 Dec 15;315:150-9
pubmed: 27506656
Trends Neurosci. 2011 Aug;34(8):411-20
pubmed: 21764143
Prev Med. 2016 Nov;92:135-140
pubmed: 27471021
Addiction. 2014 Sep;109(9):1541-53
pubmed: 24916157
Neuropsychopharmacology. 2018 Sep;43(10):2118-2125
pubmed: 29472646
Nicotine Tob Res. 2015 Apr;17(4):486-95
pubmed: 25762760
Physiol Rev. 2007 Oct;87(4):1113-73
pubmed: 17928582
Biol Psychiatry. 2010 Apr 15;67(8):722-9
pubmed: 20172508
Eur J Neurosci. 2005 Mar;21(6):1703-11
pubmed: 15845097
PLoS One. 2012;7(4):e35538
pubmed: 22514749
Psychopharmacology (Berl). 2000 Dec;153(1):31-43
pubmed: 11255927
Hum Psychopharmacol. 2009 Oct;24(7):559-64
pubmed: 19743227
Eur J Pharmacol. 2001 Dec 7;432(2-3):153-61
pubmed: 11740951
J Consult Clin Psychol. 1996 Apr;64(2):366-79
pubmed: 8871421
J Neurosci. 2016 Aug 17;36(33):8612-23
pubmed: 27535909
J Neurosci. 2014 Dec 10;34(50):16851-5
pubmed: 25505336
Neuropsychopharmacology. 2014 Sep;39(10):2376-86
pubmed: 24713611
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
J Neurochem. 2012 Aug;122(3):628-40
pubmed: 22578217
Exp Clin Psychopharmacol. 2010 Dec;18(6):451-61
pubmed: 21186920
Physiol Behav. 2014 Jan 17;123:187-92
pubmed: 24184415
Psychopharmacology (Berl). 2008 Jun;198(2):201-10
pubmed: 18338157
Neurosci Biobehav Rev. 2015 Nov;58:168-85
pubmed: 26054790
J Neurosci Res. 2017 Jan 2;95(1-2):148-162
pubmed: 27870459
Pharmacol Biochem Behav. 1995 Jun-Jul;51(2-3):457-61
pubmed: 7667368
Psychopharmacology (Berl). 2006 Mar;184(3-4):353-66
pubmed: 16240165
Pharmacol Biochem Behav. 2009 Nov;94(1):43-50
pubmed: 19619575
Neuroscience. 2001;105(3):535-45
pubmed: 11516821
Eur J Pharmacol. 1995 Jun 6;279(1):59-64
pubmed: 7556383
Neurobiol Stress. 2018 Jun 02;9:271-285
pubmed: 30450391
Neuropsychopharmacology. 2010 Oct;35(11):2165-78
pubmed: 20613718
Neuropsychopharmacology. 2000 Aug;23(2):138-50
pubmed: 10882840
Sheng Li Xue Bao. 2007 Dec 25;59(6):739-44
pubmed: 18157465
Neuropharmacology. 2010 Feb;58(2):374-82
pubmed: 19833142
Neuropharmacology. 2007 Dec;53(8):958-66
pubmed: 17976662
Pharmacol Biochem Behav. 2015 Feb 28;132:56-62
pubmed: 25735492
Neuropharmacology. 2014 Jan;76 Pt B:566-80
pubmed: 23684991
Behav Brain Res. 2014 May 1;264:143-50
pubmed: 24508239
Drug Alcohol Depend. 2013 Nov 1;133(1):52-60
pubmed: 23810373
Psychopharmacology (Berl). 2003 Dec;170(4):409-22
pubmed: 12955296
Br J Addict. 1991 Aug;86(8):991-8
pubmed: 1833003
Drug Alcohol Depend. 2017 Oct 1;179:275-279
pubmed: 28823835
Nicotine Tob Res. 2017 Mar 1;19(3):273-281
pubmed: 27613893
J Pharmacol Exp Ther. 2001 Jan;296(1):132-40
pubmed: 11123373
Eur J Neurosci. 2010 Feb;31(4):733-41
pubmed: 20384816
Nicotine Tob Res. 2015 Apr;17(4):443-8
pubmed: 25762754
Addiction. 2008 May;103(5):809-21
pubmed: 18412759
Neurosci Lett. 1997 Jul 18;230(2):140-2
pubmed: 9259484
Neuron. 2017 Oct 11;96(2):414-427.e8
pubmed: 29024664
Psychopharmacology (Berl). 2005 Apr;178(4):481-92
pubmed: 15765262
Behav Pharmacol. 2009 Feb;20(1):109-13
pubmed: 19179854
J Neurosci. 2016 Sep 21;36(38):9937-48
pubmed: 27656031
Neuropsychopharmacology. 2001 Oct;25(4):601-7
pubmed: 11557173
Curr Neuropharmacol. 2018;16(4):403-414
pubmed: 29110618
Nicotine Tob Res. 2008 Nov;10(11):1653-61
pubmed: 18988078
Cereb Cortex. 2009 Oct;19(10):2479-84
pubmed: 19193712
Pharmacol Biochem Behav. 2005 Sep;82(1):163-9
pubmed: 16143377
Drug Alcohol Depend. 2012 Mar 1;121(3):240-6
pubmed: 21945235
Neuroscience. 2004;129(3):719-25
pubmed: 15541892
Addict Behav. 2018 Dec;87:82-85
pubmed: 29966963
Nicotine Tob Res. 2015 Apr;17(4):463-72
pubmed: 25762757
Behav Brain Res. 2016 Jul 1;307:258-63
pubmed: 27059334
JAMA. 2006 Jul 5;296(1):56-63
pubmed: 16820547
Neurosci Biobehav Rev. 2012 May;36(5):1418-41
pubmed: 22405889
Front Psychiatry. 2017 May 01;8:65
pubmed: 28507522
Nat Neurosci. 2016 Apr 26;19(6):656-664
pubmed: 29162973
Psychopharmacology (Berl). 2009 Oct;206(2):303-12
pubmed: 19629450
Pharmacol Biochem Behav. 2004 Jan;77(1):21-8
pubmed: 14724038
J Psychopharmacol. 2015 Mar;29(3):300-11
pubmed: 25516371
Neuropharmacology. 2011 Feb-Mar;60(2-3):303-11
pubmed: 20854830
Neuropharmacology. 2011 Jul-Aug;61(1-2):189-201
pubmed: 21504750
Neurotox Res. 2011 Oct;20(3):226-39
pubmed: 21191826
Biol Psychiatry. 2007 Jan 1;61(1):127-35
pubmed: 16631128
Synapse. 2016 Aug;70(8):336-46
pubmed: 27074301
Neuropsychopharmacology. 2009 Jul;34(8):1993-2001
pubmed: 19212318
Handb Exp Pharmacol. 2009;(192):261-91
pubmed: 19184653
Cold Spring Harb Perspect Med. 2013 Jan 01;3(1):a012112
pubmed: 23143843
Addict Biol. 2007 Sep;12(3-4):227-462
pubmed: 17678505
Psychopharmacology (Berl). 2001 Jun;156(1):98-107
pubmed: 11465640
Psychopharmacology (Berl). 2015 Oct;232(19):3539-49
pubmed: 26146014
J Neurosci. 2004 Feb 18;24(7):1551-60
pubmed: 14973230